Predicting Responses to a Targeted Therapy
A decrease in a specific population of circulating tumor cells over two months of crizotinib treatment associated with progression-free survival.
Progress Against Cancer
A decrease in a specific population of circulating tumor cells over two months of crizotinib treatment associated with progression-free survival.
A study describes a biomarker to predict immunotherapy response early in the course of treatment and a noninvasive imaging method to detect this biomarker.
A study connects alcohol consumption with an increased risk of most types of breast cancer among African-American women. For the past decade, researchers have known that alcohol raises the risk of breast cancer. But...
The FDA expanded the use of regorafenib to treat certain patients with the most common form of liver cancer diagnosed in the U.S. – hepatocellular carcinoma.
The FDA approved a molecularly targeted therapeutic for the maintenance treatment of patients with recurrent epithelial ovarian and other cancers.
The FDA issued the first-ever approval of a treatment for patients with a rare, aggressive form of skin cancer called Merkel cell carcinoma.
The FDA expanded the use of the immunotherapeutic pembrolizumab to include the treatment of certain patients with Hodgkin lymphoma.
A molecularly targeted therapeutic was approved for use in combination with any aromatase inhibitor for the treatment of postmenopausal women with a certain form of breast cancer.
Study reports that cancer type and mortality differs among ethnic groups, suggesting a need for targeted public health efforts. A new study suggests that the growing Hispanic population in the United States may experience...
A study suggests that diet during adolescence and early adulthood may be associated with premenopausal breast cancer risk.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More